News – Page 74 – Endpoints News

Novartis to cut 139 jobs in NJ as part of commercial refocus

6 months ago

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

6 months ago

Outlook's shares crash as wet AMD drug flunks Phase 3 test

6 months ago

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

6 months ago

Bristol Myers sues the federal government over 340B, following other drugmakers

6 months ago

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

6 months ago

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

6 months ago

Acadia snaps up an essential tremor drug after field's summer setbacks

6 months ago

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

6 months ago

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

6 months ago

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

6 months ago

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

6 months ago

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

6 months ago

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

6 months ago

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

6 months ago

Agilent reveals plans to remodel operations as annual revenue dips

6 months ago

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

6 months ago

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

6 months ago

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

6 months ago

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

6 months ago

Cradle Bio raises $73M Series B to sell pharma its protein-making AI software

6 months ago

Why Morgan Health is backing an autism care company

6 months ago

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

6 months ago

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

6 months ago

First page Previous page 71 72 737475 76 77 Next page Last page